Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
10 05 2022
10 05 2022
Historique:
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
14
5
2022
Statut:
ppublish
Résumé
Chronic obstructive pulmonary disease (COPD) is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of deterioration of lung function. In 2020 it was estimated that approximately 6% of US adults had been diagnosed with COPD. Chronic lower respiratory disease, composed mainly of COPD, is the sixth leading cause of death in the US. To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update that focused on targeted key questions for benefits and harms of screening for COPD in asymptomatic adults and treatment in screen-detected or screen-relevant adults. Asymptomatic adults who do not recognize or report respiratory symptoms. Using a reaffirmation process, the USPSTF concludes with moderate certainty that screening for COPD in asymptomatic adults has no net benefit. The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation).
Identifiants
pubmed: 35536260
pii: 2791924
doi: 10.1001/jama.2022.5692
doi:
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
1806-1811Commentaires et corrections
Type : SummaryForPatientsIn
Type : CommentIn